MAS825
- Generic Name
- MAS825
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Phase 2
Active, not recruiting
- Conditions
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
- Interventions
- Biological: PlaceboBiological: MAS825
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT04641442
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Children´s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children´s Hospital, Houston, Texas, United States
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2
Active, not recruiting
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: LYS006Drug: Placebo to LYS006Drug: Placebo to MAS825Drug: Placebo to CFZ533Drug: LOU064 25mgDrug: CFZ533Drug: LOU064 100mgDrug: Placebo to VAY736Drug: VAY736Drug: Placebo to LOU064Drug: MAS825
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT03827798
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Olympian Clinical Research ., Clearwater, Florida, United States
🇺🇸Park Avenue Dermatology, PA, Orange Park, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath